High-Flow Nasal Cannula versus Conventional Oxygen Therapy for Patients with Acute Respiratory Failure in the Emergency Department: A Randomized Controlled Trial
Abstract
Background: To compare the efficacy of a high-flow nasal cannula (HFNC) versus conventional oxygen therapy (COT) in the treatment of patients admitted to the emergency department (ED) for acute respiratory failure (ARF). Materials and Methods: In this prospective randomized clinical trial, 66 patients aged 18 years or older who presented with ARF to the ED were enrolled and assigned into two equal groups to receive either COT or HFNC for 60 minutes. The primary outcome was the intubation rates. The secondary outcomes were the effect of intervention on oxygenation, ICU admission rate, and effect on physiologic variables. Results: 33 patients were treated in each group. The main causes of ARF were chronic obstructive pulmonary disease (COPD), pneumonia, and asthma. The need for intubation was higher in COT than in HFNC (42.5% vs 12.1%, P = 0.004). Patients with HFNC had a higher dyspnea improvement than those treated with COT (93.9% vs 63.7%, P = 0.002). They also showed greater improvement in oxygen saturation (increase in SpO2 was 8.3% vs. −0.5, difference 8.8% (6.8 to 10.9)), and in respiratory rate (decrease 3.0 beats/min vs 0.2 beats/min, differences 2.8(0.8 to 4.6)). The ICU admission was higher in the COT group (51.5 vs 15.2, P=0.002). Conclusion: HFNC reduced the need for intubation and ICU admission in the patients presenting to the ED with ARF compared with COT. In addition, HFNC was associated with a greater reduction in RR and improvement in SpO2 compared with COT.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 66 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.